These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. An evaluation of the severity and progression of epistaxis in hereditary hemorrhagic telangiectasia 1 versus hereditary hemorrhagic telangiectasia 2. Hunter BN; Timmins BH; McDonald J; Whitehead KJ; Ward PD; Wilson KF Laryngoscope; 2016 Apr; 126(4):786-90. PubMed ID: 26372311 [TBL] [Abstract][Full Text] [Related]
25. Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease. Gaillard S; Dupuis-Girod S; Boutitie F; Rivière S; Morinière S; Hatron PY; Manfredi G; Kaminsky P; Capitaine AL; Roy P; Gueyffier F; Plauchu H; J Thromb Haemost; 2014 Sep; 12(9):1494-502. PubMed ID: 25040799 [TBL] [Abstract][Full Text] [Related]
26. The effects of epistaxis on health-related quality of life in patients with hereditary hemorrhagic telangiectasia. Merlo CA; Yin LX; Hoag JB; Mitchell SE; Reh DD Int Forum Allergy Rhinol; 2014 Nov; 4(11):921-5. PubMed ID: 25145809 [TBL] [Abstract][Full Text] [Related]
27. The effects of nasal closure on quality of life in patients with hereditary hemorrhagic telangiectasia. Thomson RS; Molin NL; Whitehead KJ; Ashby S; Johnson L; Ward PD; McRae BR; Wilson KF; McDonald J Laryngoscope Investig Otolaryngol; 2018 Jun; 3(3):178-181. PubMed ID: 30062132 [TBL] [Abstract][Full Text] [Related]
28. Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid - a double-blind placebo-controlled cross-over phase IIIB study. Geisthoff UW; Seyfert UT; Kübler M; Bieg B; Plinkert PK; König J Thromb Res; 2014 Sep; 134(3):565-71. PubMed ID: 25005464 [TBL] [Abstract][Full Text] [Related]
30. Weekly epistaxis duration as an indicator of epistaxis severity in hereditary hemorrhagic telangiectasia-Preliminary results from a randomized controlled trial. Wu V; Lee JM; Vozoris NT; Faughnan ME Laryngoscope Investig Otolaryngol; 2021 Jun; 6(3):370-375. PubMed ID: 34195356 [TBL] [Abstract][Full Text] [Related]
31. Propranolol as antiangiogenic candidate for the therapy of hereditary haemorrhagic telangiectasia. Albiñana V; Recio-Poveda L; Zarrabeitia R; Bernabéu C; Botella LM Thromb Haemost; 2012 Jul; 108(1):41-53. PubMed ID: 22552254 [TBL] [Abstract][Full Text] [Related]
32. Intranasal bevacizumab treatment on epistaxis in hereditary haemorrhagic telangiectasia: a case report. García-Martín E; Pernía-López S; Martínez-Ortega PA; Monje B; Ruiz-Martínez C; Sanjurjo-Saez M Eur J Hosp Pharm; 2019 Jul; 26(4):226-228. PubMed ID: 31338174 [TBL] [Abstract][Full Text] [Related]
33. Medical Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Meta-analysis. Hsu YP; Hsu CW; Bai CH; Cheng SW; Chen C Otolaryngol Head Neck Surg; 2019 Jan; 160(1):22-35. PubMed ID: 30200816 [TBL] [Abstract][Full Text] [Related]
34. Correlation of severity of epistaxis with nasal telangiectasias in hereditary hemorrhagic telangiectasia (HHT) patients. Pagella F; Colombo A; Matti E; Giourgos G; Tinelli C; Olivieri C; Danesino C Am J Rhinol Allergy; 2009; 23(1):52-8. PubMed ID: 19379613 [TBL] [Abstract][Full Text] [Related]
35. North American Study for the Treatment of Recurrent Epistaxis with Doxycycline: The NOSTRIL trial. McWilliams JP; Majumdar S; Kim GH; Lee J; Seals K; Tangchaiburana S; Gilbert S; Duckwiler GR J Thromb Haemost; 2022 May; 20(5):1115-1125. PubMed ID: 35108451 [TBL] [Abstract][Full Text] [Related]
36. Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis. Karnezis TT; Davidson TM Laryngoscope; 2011 Mar; 121(3):636-8. PubMed ID: 21344445 [TBL] [Abstract][Full Text] [Related]
37. Antiestrogen therapy for hereditary hemorrhagic telangiectasia: a double-blind placebo-controlled clinical trial. Yaniv E; Preis M; Hadar T; Shvero J; Haddad M Laryngoscope; 2009 Feb; 119(2):284-8. PubMed ID: 19160429 [TBL] [Abstract][Full Text] [Related]
38. Nasal Endoscopy in the Clinical Diagnosis of Hereditary Hemorrhagic Telangiectasia. Matti E; Lizzio R; Ugolini S; Maiorano E; Zaccari D; De Silvestri A; De Sando E; Marseglia GL; Benazzo M; Olivieri C; Pagella F; Spinozzi G J Pediatr; 2021 Nov; 238():74-79.e2. PubMed ID: 34265342 [TBL] [Abstract][Full Text] [Related]
39. Treatment of severe refractory epistaxis in hereditary hemorrhagic telangiectasia using a two-flap nasal closure method. Timmins BH; Hunter BN; Wilson KF; Ward PD Int Forum Allergy Rhinol; 2016 May; 6(5):544-8. PubMed ID: 26751606 [TBL] [Abstract][Full Text] [Related]